nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—Mass—Capecitabine—esophageal cancer	0.0318	0.0436	CcSEcCtD
Naratriptan—Diuresis—Cisplatin—esophageal cancer	0.0202	0.0277	CcSEcCtD
Naratriptan—Pain in jaw—Capecitabine—esophageal cancer	0.0142	0.0194	CcSEcCtD
Naratriptan—Pleurisy—Methotrexate—esophageal cancer	0.0141	0.0193	CcSEcCtD
Naratriptan—Vasospasm—Capecitabine—esophageal cancer	0.0135	0.0185	CcSEcCtD
Naratriptan—Eletriptan—CYP2A6—esophageal cancer	0.0103	0.385	CrCbGaD
Naratriptan—Altered state of consciousness—Capecitabine—esophageal cancer	0.00999	0.0137	CcSEcCtD
Naratriptan—Transient ischaemic attack—Capecitabine—esophageal cancer	0.00914	0.0125	CcSEcCtD
Naratriptan—Balance disorder—Capecitabine—esophageal cancer	0.00844	0.0116	CcSEcCtD
Naratriptan—Cognitive disorder—Methotrexate—esophageal cancer	0.00794	0.0109	CcSEcCtD
Naratriptan—Gastric ulcer—Capecitabine—esophageal cancer	0.00794	0.0109	CcSEcCtD
Naratriptan—Eletriptan—PTGS1—esophageal cancer	0.00791	0.295	CrCbGaD
Naratriptan—Haemorrhoids—Capecitabine—esophageal cancer	0.00785	0.0108	CcSEcCtD
Naratriptan—Infection—Carboplatin—esophageal cancer	0.00756	0.0104	CcSEcCtD
Naratriptan—Hypothyroidism—Capecitabine—esophageal cancer	0.00719	0.00986	CcSEcCtD
Naratriptan—Aphasia—Capecitabine—esophageal cancer	0.00711	0.00976	CcSEcCtD
Naratriptan—Neuralgia—Capecitabine—esophageal cancer	0.00664	0.00911	CcSEcCtD
Naratriptan—Ulcer—Cisplatin—esophageal cancer	0.00662	0.00908	CcSEcCtD
Naratriptan—Pain—Carboplatin—esophageal cancer	0.00651	0.00893	CcSEcCtD
Naratriptan—Ventricular fibrillation—Capecitabine—esophageal cancer	0.00602	0.00827	CcSEcCtD
Naratriptan—Body temperature increased—Carboplatin—esophageal cancer	0.00602	0.00826	CcSEcCtD
Naratriptan—Fluid retention—Cisplatin—esophageal cancer	0.00594	0.00815	CcSEcCtD
Naratriptan—Hyperaesthesia—Capecitabine—esophageal cancer	0.00588	0.00807	CcSEcCtD
Naratriptan—Tingling sensation—Capecitabine—esophageal cancer	0.00574	0.00787	CcSEcCtD
Naratriptan—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00574	0.00787	CcSEcCtD
Naratriptan—Folliculitis—Methotrexate—esophageal cancer	0.00546	0.0075	CcSEcCtD
Naratriptan—Aphasia—Methotrexate—esophageal cancer	0.00529	0.00727	CcSEcCtD
Naratriptan—Polyuria—Cisplatin—esophageal cancer	0.00517	0.0071	CcSEcCtD
Naratriptan—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00514	0.00706	CcSEcCtD
Naratriptan—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.00511	0.00701	CcSEcCtD
Naratriptan—Paralysis—Methotrexate—esophageal cancer	0.00494	0.00678	CcSEcCtD
Naratriptan—Burning sensation—Methotrexate—esophageal cancer	0.00494	0.00678	CcSEcCtD
Naratriptan—Ulcer—Capecitabine—esophageal cancer	0.00488	0.00669	CcSEcCtD
Naratriptan—Bone pain—Capecitabine—esophageal cancer	0.00482	0.00661	CcSEcCtD
Naratriptan—Inflammation—Capecitabine—esophageal cancer	0.00476	0.00653	CcSEcCtD
Naratriptan—Sumatriptan—ABCB1—esophageal cancer	0.00475	0.177	CrCbGaD
Naratriptan—Coordination abnormal—Capecitabine—esophageal cancer	0.0047	0.00645	CcSEcCtD
Naratriptan—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00469	0.00644	CcSEcCtD
Naratriptan—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00464	0.00636	CcSEcCtD
Naratriptan—Blood pressure increased—Capecitabine—esophageal cancer	0.00461	0.00633	CcSEcCtD
Naratriptan—Urinary incontinence—Capecitabine—esophageal cancer	0.00445	0.00611	CcSEcCtD
Naratriptan—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00445	0.00611	CcSEcCtD
Naratriptan—Fluid retention—Capecitabine—esophageal cancer	0.00438	0.00601	CcSEcCtD
Naratriptan—Dry eye—Capecitabine—esophageal cancer	0.00426	0.00585	CcSEcCtD
Naratriptan—Dehydration—Cisplatin—esophageal cancer	0.00422	0.0058	CcSEcCtD
Naratriptan—Oesophagitis—Capecitabine—esophageal cancer	0.00422	0.00578	CcSEcCtD
Naratriptan—Urine output increased—Capecitabine—esophageal cancer	0.00417	0.00572	CcSEcCtD
Naratriptan—Cramp muscle—Cisplatin—esophageal cancer	0.00409	0.00561	CcSEcCtD
Naratriptan—Sleep disorder—Capecitabine—esophageal cancer	0.00387	0.00531	CcSEcCtD
Naratriptan—Eletriptan—ABCB1—esophageal cancer	0.00385	0.143	CrCbGaD
Naratriptan—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00383	0.00525	CcSEcCtD
Naratriptan—Photosensitivity—Capecitabine—esophageal cancer	0.00381	0.00523	CcSEcCtD
Naratriptan—Polyuria—Capecitabine—esophageal cancer	0.00381	0.00523	CcSEcCtD
Naratriptan—Swelling—Capecitabine—esophageal cancer	0.0038	0.00521	CcSEcCtD
Naratriptan—Gastroenteritis—Capecitabine—esophageal cancer	0.00378	0.00518	CcSEcCtD
Naratriptan—Abdominal discomfort—Cisplatin—esophageal cancer	0.00376	0.00517	CcSEcCtD
Naratriptan—Vascular purpura—Capecitabine—esophageal cancer	0.00374	0.00514	CcSEcCtD
Naratriptan—Eye pain—Capecitabine—esophageal cancer	0.00371	0.00509	CcSEcCtD
Naratriptan—Ulcer—Methotrexate—esophageal cancer	0.00363	0.00498	CcSEcCtD
Naratriptan—Libido decreased—Capecitabine—esophageal cancer	0.00361	0.00496	CcSEcCtD
Naratriptan—Inflammation—Methotrexate—esophageal cancer	0.00354	0.00486	CcSEcCtD
Naratriptan—Atrial fibrillation—Capecitabine—esophageal cancer	0.00353	0.00485	CcSEcCtD
Naratriptan—Thirst—Capecitabine—esophageal cancer	0.00352	0.00483	CcSEcCtD
Naratriptan—Purpura—Capecitabine—esophageal cancer	0.00347	0.00477	CcSEcCtD
Naratriptan—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00345	0.00474	CcSEcCtD
Naratriptan—Vaginal inflammation—Methotrexate—esophageal cancer	0.00343	0.00471	CcSEcCtD
Naratriptan—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00343	0.00471	CcSEcCtD
Naratriptan—Myocardial infarction—Cisplatin—esophageal cancer	0.00343	0.00471	CcSEcCtD
Naratriptan—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00342	0.00469	CcSEcCtD
Naratriptan—Cystitis noninfective—Methotrexate—esophageal cancer	0.00335	0.0046	CcSEcCtD
Naratriptan—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00332	0.00456	CcSEcCtD
Naratriptan—Cystitis—Methotrexate—esophageal cancer	0.00332	0.00455	CcSEcCtD
Naratriptan—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00332	0.00455	CcSEcCtD
Naratriptan—Migraine—Capecitabine—esophageal cancer	0.0033	0.00452	CcSEcCtD
Naratriptan—Vaginal infection—Methotrexate—esophageal cancer	0.00324	0.00445	CcSEcCtD
Naratriptan—Bradycardia—Cisplatin—esophageal cancer	0.0032	0.00439	CcSEcCtD
Naratriptan—Dehydration—Capecitabine—esophageal cancer	0.00311	0.00427	CcSEcCtD
Naratriptan—Urine output increased—Methotrexate—esophageal cancer	0.0031	0.00426	CcSEcCtD
Naratriptan—Bladder pain—Methotrexate—esophageal cancer	0.0031	0.00426	CcSEcCtD
Naratriptan—Liver function test abnormal—Capecitabine—esophageal cancer	0.00309	0.00424	CcSEcCtD
Naratriptan—Dry skin—Capecitabine—esophageal cancer	0.00307	0.00421	CcSEcCtD
Naratriptan—Gastritis—Capecitabine—esophageal cancer	0.00296	0.00407	CcSEcCtD
Naratriptan—Tinnitus—Cisplatin—esophageal cancer	0.00293	0.00402	CcSEcCtD
Naratriptan—Cardiac disorder—Cisplatin—esophageal cancer	0.00292	0.004	CcSEcCtD
Naratriptan—Asthma—Capecitabine—esophageal cancer	0.00289	0.00397	CcSEcCtD
Naratriptan—Photosensitivity—Methotrexate—esophageal cancer	0.00284	0.0039	CcSEcCtD
Naratriptan—Polyuria—Methotrexate—esophageal cancer	0.00284	0.0039	CcSEcCtD
Naratriptan—Immune system disorder—Cisplatin—esophageal cancer	0.00284	0.0039	CcSEcCtD
Naratriptan—Angina pectoris—Capecitabine—esophageal cancer	0.00282	0.00387	CcSEcCtD
Naratriptan—Arrhythmia—Cisplatin—esophageal cancer	0.00281	0.00385	CcSEcCtD
Naratriptan—Bronchitis—Capecitabine—esophageal cancer	0.00278	0.00382	CcSEcCtD
Naratriptan—Alopecia—Cisplatin—esophageal cancer	0.00278	0.00381	CcSEcCtD
Naratriptan—Abdominal discomfort—Capecitabine—esophageal cancer	0.00277	0.00381	CcSEcCtD
Naratriptan—Erythema—Cisplatin—esophageal cancer	0.00274	0.00375	CcSEcCtD
Naratriptan—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00264	0.00363	CcSEcCtD
Naratriptan—Muscle spasms—Cisplatin—esophageal cancer	0.00263	0.00361	CcSEcCtD
Naratriptan—Hyperglycaemia—Capecitabine—esophageal cancer	0.00261	0.00358	CcSEcCtD
Naratriptan—Pneumonia—Capecitabine—esophageal cancer	0.0026	0.00356	CcSEcCtD
Naratriptan—Vision blurred—Cisplatin—esophageal cancer	0.00258	0.00354	CcSEcCtD
Naratriptan—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00258	0.00353	CcSEcCtD
Naratriptan—Depression—Capecitabine—esophageal cancer	0.00257	0.00353	CcSEcCtD
Naratriptan—Tremor—Cisplatin—esophageal cancer	0.00256	0.00352	CcSEcCtD
Naratriptan—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00254	0.00349	CcSEcCtD
Naratriptan—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00254	0.00349	CcSEcCtD
Naratriptan—Ill-defined disorder—Cisplatin—esophageal cancer	0.00254	0.00348	CcSEcCtD
Naratriptan—Myocardial infarction—Capecitabine—esophageal cancer	0.00253	0.00347	CcSEcCtD
Naratriptan—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00253	0.00347	CcSEcCtD
Naratriptan—Anaemia—Cisplatin—esophageal cancer	0.00253	0.00347	CcSEcCtD
Naratriptan—Malaise—Cisplatin—esophageal cancer	0.00247	0.00339	CcSEcCtD
Naratriptan—Convulsion—Cisplatin—esophageal cancer	0.00237	0.00325	CcSEcCtD
Naratriptan—Bradycardia—Capecitabine—esophageal cancer	0.00236	0.00324	CcSEcCtD
Naratriptan—Myalgia—Cisplatin—esophageal cancer	0.00233	0.0032	CcSEcCtD
Naratriptan—Haemoglobin—Capecitabine—esophageal cancer	0.00233	0.0032	CcSEcCtD
Naratriptan—Anxiety—Cisplatin—esophageal cancer	0.00232	0.00318	CcSEcCtD
Naratriptan—Haemorrhage—Capecitabine—esophageal cancer	0.00232	0.00318	CcSEcCtD
Naratriptan—Hypoaesthesia—Capecitabine—esophageal cancer	0.00231	0.00316	CcSEcCtD
Naratriptan—Liver function test abnormal—Methotrexate—esophageal cancer	0.0023	0.00316	CcSEcCtD
Naratriptan—Discomfort—Cisplatin—esophageal cancer	0.0023	0.00316	CcSEcCtD
Naratriptan—Anaphylactic shock—Cisplatin—esophageal cancer	0.00223	0.00306	CcSEcCtD
Naratriptan—Oedema—Cisplatin—esophageal cancer	0.00223	0.00306	CcSEcCtD
Naratriptan—Infection—Cisplatin—esophageal cancer	0.00222	0.00304	CcSEcCtD
Naratriptan—Nervous system disorder—Cisplatin—esophageal cancer	0.00219	0.003	CcSEcCtD
Naratriptan—Thrombocytopenia—Cisplatin—esophageal cancer	0.00219	0.003	CcSEcCtD
Naratriptan—Skin disorder—Cisplatin—esophageal cancer	0.00217	0.00298	CcSEcCtD
Naratriptan—Tinnitus—Capecitabine—esophageal cancer	0.00216	0.00296	CcSEcCtD
Naratriptan—Hyperhidrosis—Cisplatin—esophageal cancer	0.00216	0.00296	CcSEcCtD
Naratriptan—Asthma—Methotrexate—esophageal cancer	0.00215	0.00296	CcSEcCtD
Naratriptan—Cardiac disorder—Capecitabine—esophageal cancer	0.00215	0.00295	CcSEcCtD
Naratriptan—Angiopathy—Capecitabine—esophageal cancer	0.0021	0.00288	CcSEcCtD
Naratriptan—Immune system disorder—Capecitabine—esophageal cancer	0.00209	0.00287	CcSEcCtD
Naratriptan—Hypotension—Cisplatin—esophageal cancer	0.00209	0.00286	CcSEcCtD
Naratriptan—Chills—Capecitabine—esophageal cancer	0.00208	0.00285	CcSEcCtD
Naratriptan—Arrhythmia—Capecitabine—esophageal cancer	0.00207	0.00284	CcSEcCtD
Naratriptan—Abdominal discomfort—Methotrexate—esophageal cancer	0.00207	0.00283	CcSEcCtD
Naratriptan—Alopecia—Capecitabine—esophageal cancer	0.00205	0.00281	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00203	0.00279	CcSEcCtD
Naratriptan—Erythema—Capecitabine—esophageal cancer	0.00202	0.00277	CcSEcCtD
Naratriptan—Paraesthesia—Cisplatin—esophageal cancer	0.002	0.00275	CcSEcCtD
Naratriptan—Dyspnoea—Cisplatin—esophageal cancer	0.00199	0.00273	CcSEcCtD
Naratriptan—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00197	0.0027	CcSEcCtD
Naratriptan—Muscle spasms—Capecitabine—esophageal cancer	0.00194	0.00266	CcSEcCtD
Naratriptan—Pneumonia—Methotrexate—esophageal cancer	0.00193	0.00265	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00193	0.00265	CcSEcCtD
Naratriptan—Drowsiness—Methotrexate—esophageal cancer	0.00192	0.00264	CcSEcCtD
Naratriptan—Depression—Methotrexate—esophageal cancer	0.00192	0.00263	CcSEcCtD
Naratriptan—Pain—Cisplatin—esophageal cancer	0.00191	0.00262	CcSEcCtD
Naratriptan—Vision blurred—Capecitabine—esophageal cancer	0.0019	0.00261	CcSEcCtD
Naratriptan—Tremor—Capecitabine—esophageal cancer	0.00189	0.00259	CcSEcCtD
Naratriptan—Ill-defined disorder—Capecitabine—esophageal cancer	0.00187	0.00257	CcSEcCtD
Naratriptan—Anaemia—Capecitabine—esophageal cancer	0.00186	0.00256	CcSEcCtD
Naratriptan—Sweating—Methotrexate—esophageal cancer	0.00184	0.00253	CcSEcCtD
Naratriptan—Feeling abnormal—Cisplatin—esophageal cancer	0.00184	0.00252	CcSEcCtD
Naratriptan—Malaise—Capecitabine—esophageal cancer	0.00182	0.0025	CcSEcCtD
Naratriptan—Vertigo—Capecitabine—esophageal cancer	0.00181	0.00249	CcSEcCtD
Naratriptan—Syncope—Capecitabine—esophageal cancer	0.00181	0.00248	CcSEcCtD
Naratriptan—Palpitations—Capecitabine—esophageal cancer	0.00178	0.00245	CcSEcCtD
Naratriptan—Loss of consciousness—Capecitabine—esophageal cancer	0.00177	0.00243	CcSEcCtD
Naratriptan—Body temperature increased—Cisplatin—esophageal cancer	0.00177	0.00242	CcSEcCtD
Naratriptan—Cough—Capecitabine—esophageal cancer	0.00176	0.00241	CcSEcCtD
Naratriptan—Haemoglobin—Methotrexate—esophageal cancer	0.00173	0.00238	CcSEcCtD
Naratriptan—Haemorrhage—Methotrexate—esophageal cancer	0.00172	0.00237	CcSEcCtD
Naratriptan—Myalgia—Capecitabine—esophageal cancer	0.00172	0.00236	CcSEcCtD
Naratriptan—Arthralgia—Capecitabine—esophageal cancer	0.00172	0.00236	CcSEcCtD
Naratriptan—Anxiety—Capecitabine—esophageal cancer	0.00171	0.00235	CcSEcCtD
Naratriptan—Discomfort—Capecitabine—esophageal cancer	0.0017	0.00233	CcSEcCtD
Naratriptan—Dry mouth—Capecitabine—esophageal cancer	0.00168	0.0023	CcSEcCtD
Naratriptan—Confusional state—Capecitabine—esophageal cancer	0.00166	0.00228	CcSEcCtD
Naratriptan—Oedema—Capecitabine—esophageal cancer	0.00165	0.00226	CcSEcCtD
Naratriptan—Hypersensitivity—Cisplatin—esophageal cancer	0.00165	0.00226	CcSEcCtD
Naratriptan—Infection—Capecitabine—esophageal cancer	0.00164	0.00224	CcSEcCtD
Naratriptan—Shock—Capecitabine—esophageal cancer	0.00162	0.00222	CcSEcCtD
Naratriptan—Nervous system disorder—Capecitabine—esophageal cancer	0.00161	0.00221	CcSEcCtD
Naratriptan—Thrombocytopenia—Capecitabine—esophageal cancer	0.00161	0.00221	CcSEcCtD
Naratriptan—Tinnitus—Methotrexate—esophageal cancer	0.00161	0.00221	CcSEcCtD
Naratriptan—Asthenia—Cisplatin—esophageal cancer	0.0016	0.0022	CcSEcCtD
Naratriptan—Cardiac disorder—Methotrexate—esophageal cancer	0.0016	0.0022	CcSEcCtD
Naratriptan—Skin disorder—Capecitabine—esophageal cancer	0.0016	0.00219	CcSEcCtD
Naratriptan—Hyperhidrosis—Capecitabine—esophageal cancer	0.00159	0.00218	CcSEcCtD
Naratriptan—Angiopathy—Methotrexate—esophageal cancer	0.00156	0.00215	CcSEcCtD
Naratriptan—Immune system disorder—Methotrexate—esophageal cancer	0.00156	0.00214	CcSEcCtD
Naratriptan—Chills—Methotrexate—esophageal cancer	0.00155	0.00212	CcSEcCtD
Naratriptan—Hypotension—Capecitabine—esophageal cancer	0.00154	0.00211	CcSEcCtD
Naratriptan—Diarrhoea—Cisplatin—esophageal cancer	0.00153	0.0021	CcSEcCtD
Naratriptan—Alopecia—Methotrexate—esophageal cancer	0.00152	0.00209	CcSEcCtD
Naratriptan—Erythema—Methotrexate—esophageal cancer	0.0015	0.00206	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.0015	0.00206	CcSEcCtD
Naratriptan—Paraesthesia—Capecitabine—esophageal cancer	0.00148	0.00203	CcSEcCtD
Naratriptan—Dyspnoea—Capecitabine—esophageal cancer	0.00147	0.00201	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00142	0.00195	CcSEcCtD
Naratriptan—Vomiting—Cisplatin—esophageal cancer	0.00142	0.00195	CcSEcCtD
Naratriptan—Fatigue—Capecitabine—esophageal cancer	0.00142	0.00195	CcSEcCtD
Naratriptan—Vision blurred—Methotrexate—esophageal cancer	0.00141	0.00194	CcSEcCtD
Naratriptan—Rash—Cisplatin—esophageal cancer	0.00141	0.00193	CcSEcCtD
Naratriptan—Pain—Capecitabine—esophageal cancer	0.00141	0.00193	CcSEcCtD
Naratriptan—Constipation—Capecitabine—esophageal cancer	0.00141	0.00193	CcSEcCtD
Naratriptan—Dermatitis—Cisplatin—esophageal cancer	0.00141	0.00193	CcSEcCtD
Naratriptan—Ill-defined disorder—Methotrexate—esophageal cancer	0.00139	0.00191	CcSEcCtD
Naratriptan—Anaemia—Methotrexate—esophageal cancer	0.00139	0.0019	CcSEcCtD
Naratriptan—Feeling abnormal—Capecitabine—esophageal cancer	0.00136	0.00186	CcSEcCtD
Naratriptan—Malaise—Methotrexate—esophageal cancer	0.00135	0.00186	CcSEcCtD
Naratriptan—Vertigo—Methotrexate—esophageal cancer	0.00135	0.00185	CcSEcCtD
Naratriptan—Nausea—Cisplatin—esophageal cancer	0.00133	0.00182	CcSEcCtD
Naratriptan—Cough—Methotrexate—esophageal cancer	0.00131	0.0018	CcSEcCtD
Naratriptan—Urticaria—Capecitabine—esophageal cancer	0.00131	0.00179	CcSEcCtD
Naratriptan—Body temperature increased—Capecitabine—esophageal cancer	0.0013	0.00179	CcSEcCtD
Naratriptan—Convulsion—Methotrexate—esophageal cancer	0.0013	0.00178	CcSEcCtD
Naratriptan—Myalgia—Methotrexate—esophageal cancer	0.00128	0.00175	CcSEcCtD
Naratriptan—Arthralgia—Methotrexate—esophageal cancer	0.00128	0.00175	CcSEcCtD
Naratriptan—Discomfort—Methotrexate—esophageal cancer	0.00126	0.00173	CcSEcCtD
Naratriptan—Confusional state—Methotrexate—esophageal cancer	0.00124	0.0017	CcSEcCtD
Naratriptan—Anaphylactic shock—Methotrexate—esophageal cancer	0.00123	0.00168	CcSEcCtD
Naratriptan—Infection—Methotrexate—esophageal cancer	0.00122	0.00167	CcSEcCtD
Naratriptan—Hypersensitivity—Capecitabine—esophageal cancer	0.00121	0.00166	CcSEcCtD
Naratriptan—Nervous system disorder—Methotrexate—esophageal cancer	0.0012	0.00165	CcSEcCtD
Naratriptan—Thrombocytopenia—Methotrexate—esophageal cancer	0.0012	0.00165	CcSEcCtD
Naratriptan—Skin disorder—Methotrexate—esophageal cancer	0.00119	0.00163	CcSEcCtD
Naratriptan—Hyperhidrosis—Methotrexate—esophageal cancer	0.00118	0.00163	CcSEcCtD
Naratriptan—Asthenia—Capecitabine—esophageal cancer	0.00118	0.00162	CcSEcCtD
Naratriptan—Pruritus—Capecitabine—esophageal cancer	0.00116	0.0016	CcSEcCtD
Naratriptan—Hypotension—Methotrexate—esophageal cancer	0.00114	0.00157	CcSEcCtD
Naratriptan—Diarrhoea—Capecitabine—esophageal cancer	0.00113	0.00155	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00112	0.00153	CcSEcCtD
Naratriptan—Paraesthesia—Methotrexate—esophageal cancer	0.0011	0.00151	CcSEcCtD
Naratriptan—Dyspnoea—Methotrexate—esophageal cancer	0.00109	0.0015	CcSEcCtD
Naratriptan—Somnolence—Methotrexate—esophageal cancer	0.00109	0.00149	CcSEcCtD
Naratriptan—Dizziness—Capecitabine—esophageal cancer	0.00109	0.00149	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00106	0.00145	CcSEcCtD
Naratriptan—Fatigue—Methotrexate—esophageal cancer	0.00106	0.00145	CcSEcCtD
Naratriptan—Pain—Methotrexate—esophageal cancer	0.00105	0.00144	CcSEcCtD
Naratriptan—Vomiting—Capecitabine—esophageal cancer	0.00105	0.00144	CcSEcCtD
Naratriptan—Rash—Capecitabine—esophageal cancer	0.00104	0.00142	CcSEcCtD
Naratriptan—Dermatitis—Capecitabine—esophageal cancer	0.00104	0.00142	CcSEcCtD
Naratriptan—Headache—Capecitabine—esophageal cancer	0.00103	0.00141	CcSEcCtD
Naratriptan—Feeling abnormal—Methotrexate—esophageal cancer	0.00101	0.00139	CcSEcCtD
Naratriptan—Nausea—Capecitabine—esophageal cancer	0.000978	0.00134	CcSEcCtD
Naratriptan—Urticaria—Methotrexate—esophageal cancer	0.000973	0.00134	CcSEcCtD
Naratriptan—Body temperature increased—Methotrexate—esophageal cancer	0.000969	0.00133	CcSEcCtD
Naratriptan—Hypersensitivity—Methotrexate—esophageal cancer	0.000903	0.00124	CcSEcCtD
Naratriptan—Asthenia—Methotrexate—esophageal cancer	0.000879	0.00121	CcSEcCtD
Naratriptan—Pruritus—Methotrexate—esophageal cancer	0.000867	0.00119	CcSEcCtD
Naratriptan—Diarrhoea—Methotrexate—esophageal cancer	0.000838	0.00115	CcSEcCtD
Naratriptan—Dizziness—Methotrexate—esophageal cancer	0.00081	0.00111	CcSEcCtD
Naratriptan—Vomiting—Methotrexate—esophageal cancer	0.000779	0.00107	CcSEcCtD
Naratriptan—Rash—Methotrexate—esophageal cancer	0.000773	0.00106	CcSEcCtD
Naratriptan—Dermatitis—Methotrexate—esophageal cancer	0.000772	0.00106	CcSEcCtD
Naratriptan—Headache—Methotrexate—esophageal cancer	0.000768	0.00105	CcSEcCtD
Naratriptan—Nausea—Methotrexate—esophageal cancer	0.000728	0.000999	CcSEcCtD
Naratriptan—HTR1F—Signaling Pathways—WIF1—esophageal cancer	0.000508	0.00208	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCL2—esophageal cancer	0.000499	0.00204	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—SST—esophageal cancer	0.000497	0.00203	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—GHRL—esophageal cancer	0.000484	0.00198	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000482	0.00197	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000472	0.00193	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—BLVRB—esophageal cancer	0.000471	0.00193	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—SLC52A3—esophageal cancer	0.000471	0.00193	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CSNK1A1—esophageal cancer	0.000469	0.00192	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—ANXA1—esophageal cancer	0.000464	0.0019	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CXCL2—esophageal cancer	0.000464	0.0019	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AKAP13—esophageal cancer	0.000459	0.00188	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—SST—esophageal cancer	0.000451	0.00185	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AKAP13—esophageal cancer	0.000449	0.00184	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GDI2—esophageal cancer	0.000442	0.00181	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—GHRL—esophageal cancer	0.00044	0.0018	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PFN1—esophageal cancer	0.000438	0.00179	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—ANXA1—esophageal cancer	0.000431	0.00177	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KMT2D—esophageal cancer	0.000428	0.00175	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—SST—esophageal cancer	0.00042	0.00172	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—PDE4D—esophageal cancer	0.00042	0.00172	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KMT2D—esophageal cancer	0.000419	0.00172	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AKAP13—esophageal cancer	0.000417	0.0017	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—PDE4D—esophageal cancer	0.000411	0.00168	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—GHRL—esophageal cancer	0.000409	0.00167	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AKAP13—esophageal cancer	0.000408	0.00167	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CA1—esophageal cancer	0.000401	0.00164	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—SLC10A2—esophageal cancer	0.000401	0.00164	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—GNG7—esophageal cancer	0.000399	0.00163	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ELMO1—esophageal cancer	0.000394	0.00161	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—GNG7—esophageal cancer	0.000391	0.0016	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AKAP13—esophageal cancer	0.000385	0.00157	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ADCYAP1—esophageal cancer	0.000382	0.00156	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PDE4D—esophageal cancer	0.000381	0.00156	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000378	0.00155	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ADCYAP1—esophageal cancer	0.000374	0.00153	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PDE4D—esophageal cancer	0.000373	0.00153	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CA2—esophageal cancer	0.000366	0.0015	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—GNG7—esophageal cancer	0.000362	0.00148	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000355	0.00145	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—GNG7—esophageal cancer	0.000355	0.00145	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PDE4D—esophageal cancer	0.000352	0.00144	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCL2—esophageal cancer	0.000352	0.00144	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—WWOX—esophageal cancer	0.000349	0.00143	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCL2—esophageal cancer	0.000344	0.00141	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000342	0.0014	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—WWOX—esophageal cancer	0.000342	0.0014	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PLCE1—esophageal cancer	0.000341	0.00139	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ADH7—esophageal cancer	0.000341	0.00139	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—GNG7—esophageal cancer	0.000335	0.00137	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FKBP1A—esophageal cancer	0.000332	0.00136	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—ANXA1—esophageal cancer	0.000327	0.00134	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FKBP1A—esophageal cancer	0.000325	0.00133	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—WIF1—esophageal cancer	0.000325	0.00133	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000321	0.00131	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—ANXA1—esophageal cancer	0.00032	0.00131	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KMT2D—esophageal cancer	0.00032	0.00131	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL2—esophageal cancer	0.000319	0.00131	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—SST—esophageal cancer	0.000318	0.0013	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—WIF1—esophageal cancer	0.000318	0.0013	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—XIAP—esophageal cancer	0.000314	0.00128	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000313	0.00128	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL2—esophageal cancer	0.000313	0.00128	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—SST—esophageal cancer	0.000311	0.00127	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AKAP13—esophageal cancer	0.000311	0.00127	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—GHRL—esophageal cancer	0.00031	0.00127	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—GHRL—esophageal cancer	0.000303	0.00124	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CSNK1A1—esophageal cancer	0.0003	0.00123	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ADH1B—esophageal cancer	0.000299	0.00122	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—GNG7—esophageal cancer	0.000298	0.00122	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—ANXA1—esophageal cancer	0.000297	0.00121	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CTNNA1—esophageal cancer	0.000297	0.00121	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL2—esophageal cancer	0.000295	0.00121	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CSNK1A1—esophageal cancer	0.000293	0.0012	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—ANXA1—esophageal cancer	0.000291	0.00119	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—SST—esophageal cancer	0.000289	0.00118	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—TYMP—esophageal cancer	0.000286	0.00117	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000285	0.00117	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PDE4D—esophageal cancer	0.000284	0.00116	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—SST—esophageal cancer	0.000283	0.00116	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—GHRL—esophageal cancer	0.000281	0.00115	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PFN1—esophageal cancer	0.00028	0.00115	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CYP26A1—esophageal cancer	0.000278	0.00114	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—GHRL—esophageal cancer	0.000275	0.00113	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PSME2—esophageal cancer	0.000275	0.00113	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PSME1—esophageal cancer	0.000275	0.00113	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PFN1—esophageal cancer	0.000274	0.00112	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ANXA1—esophageal cancer	0.000274	0.00112	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALOX15—esophageal cancer	0.000271	0.00111	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—GNG7—esophageal cancer	0.00027	0.00111	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SST—esophageal cancer	0.000267	0.00109	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000262	0.00107	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—WWOX—esophageal cancer	0.00026	0.00107	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—GHRL—esophageal cancer	0.00026	0.00106	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NOTCH3—esophageal cancer	0.00026	0.00106	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—TPI1—esophageal cancer	0.000258	0.00106	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GSTO1—esophageal cancer	0.000258	0.00106	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—FBXW7—esophageal cancer	0.000256	0.00105	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ELMO1—esophageal cancer	0.000252	0.00103	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FKBP1A—esophageal cancer	0.000248	0.00101	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALDOB—esophageal cancer	0.000248	0.00101	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ELMO1—esophageal cancer	0.000247	0.00101	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AKAP13—esophageal cancer	0.000246	0.00101	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000244	0.000998	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—WIF1—esophageal cancer	0.000242	0.000991	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AKAP13—esophageal cancer	0.000241	0.000986	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GAPDH—esophageal cancer	0.000238	0.000975	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL2—esophageal cancer	0.000238	0.000974	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—SST—esophageal cancer	0.000237	0.00097	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CRABP1—esophageal cancer	0.000236	0.000966	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NOTCH2—esophageal cancer	0.000233	0.000954	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—GHRL—esophageal cancer	0.000231	0.000946	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000227	0.000929	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PDE4D—esophageal cancer	0.000225	0.000921	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GNG7—esophageal cancer	0.000225	0.000919	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000223	0.000915	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000222	0.00091	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ANXA1—esophageal cancer	0.000221	0.000906	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PDE4D—esophageal cancer	0.00022	0.000902	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—SST—esophageal cancer	0.000215	0.000881	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—GNG7—esophageal cancer	0.000214	0.000876	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALDH2—esophageal cancer	0.00021	0.000861	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—GHRL—esophageal cancer	0.00021	0.000859	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—GNG7—esophageal cancer	0.00021	0.000858	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PFN1—esophageal cancer	0.000209	0.000855	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TGFBR2—esophageal cancer	0.000207	0.000846	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—XIAP—esophageal cancer	0.000201	0.000821	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GSTT1—esophageal cancer	0.0002	0.000819	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CYP2A6—esophageal cancer	0.000198	0.00081	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—XIAP—esophageal cancer	0.000196	0.000804	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SMAD4—esophageal cancer	0.000196	0.000801	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CTNNA1—esophageal cancer	0.00019	0.000776	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL2—esophageal cancer	0.000189	0.000772	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ELMO1—esophageal cancer	0.000188	0.000768	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ENO1—esophageal cancer	0.000188	0.000768	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTGS1—esophageal cancer	0.000188	0.000768	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CTNNA1—esophageal cancer	0.000186	0.00076	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PSME2—esophageal cancer	0.000185	0.000756	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PSME1—esophageal cancer	0.000185	0.000756	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL2—esophageal cancer	0.000185	0.000756	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKAP13—esophageal cancer	0.000184	0.000751	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PSME1—esophageal cancer	0.000176	0.000721	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PSME2—esophageal cancer	0.000176	0.000721	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ANXA1—esophageal cancer	0.000175	0.000717	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PSME2—esophageal cancer	0.000172	0.000706	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PSME1—esophageal cancer	0.000172	0.000706	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ANXA1—esophageal cancer	0.000172	0.000702	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SST—esophageal cancer	0.000171	0.000698	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000169	0.000693	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDE4D—esophageal cancer	0.000168	0.000687	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SST—esophageal cancer	0.000167	0.000683	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOTCH3—esophageal cancer	0.000166	0.00068	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—GHRL—esophageal cancer	0.000166	0.00068	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FBXW7—esophageal cancer	0.000164	0.000669	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOTCH3—esophageal cancer	0.000163	0.000666	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—GHRL—esophageal cancer	0.000163	0.000666	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HIF1A—esophageal cancer	0.00016	0.000655	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FBXW7—esophageal cancer	0.00016	0.000655	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GNG7—esophageal cancer	0.00016	0.000653	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CYP1B1—esophageal cancer	0.00016	0.000653	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—KDR—esophageal cancer	0.000153	0.000627	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CYP19A1—esophageal cancer	0.00015	0.000614	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—XIAP—esophageal cancer	0.00015	0.000612	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOTCH2—esophageal cancer	0.000149	0.00061	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOTCH2—esophageal cancer	0.000146	0.000597	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NOTCH1—esophageal cancer	0.000144	0.00059	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000141	0.000579	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL2—esophageal cancer	0.000141	0.000576	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—HMOX1—esophageal cancer	0.000137	0.00056	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TGFBR2—esophageal cancer	0.000132	0.000541	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PSME1—esophageal cancer	0.000131	0.000538	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PSME2—esophageal cancer	0.000131	0.000538	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ABCB1—esophageal cancer	0.000131	0.000538	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CREBBP—esophageal cancer	0.000131	0.000535	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ANXA1—esophageal cancer	0.000131	0.000535	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TGFBR2—esophageal cancer	0.000129	0.00053	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—EGFR—esophageal cancer	0.000129	0.000526	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SST—esophageal cancer	0.000127	0.000521	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SMAD4—esophageal cancer	0.000125	0.000512	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000124	0.000507	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GHRL—esophageal cancer	0.000124	0.000507	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000123	0.000503	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SMAD4—esophageal cancer	0.000123	0.000502	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FBXW7—esophageal cancer	0.000122	0.000499	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NOS3—esophageal cancer	0.000117	0.000479	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—PIK3CA—esophageal cancer	0.000112	0.000457	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOTCH2—esophageal cancer	0.000111	0.000455	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ERBB2—esophageal cancer	0.00011	0.000448	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HIF1A—esophageal cancer	0.000102	0.000419	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HIF1A—esophageal cancer	0.0001	0.00041	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TGFBR2—esophageal cancer	9.86e-05	0.000404	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KDR—esophageal cancer	9.8e-05	0.000401	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCND1—esophageal cancer	9.68e-05	0.000396	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KDR—esophageal cancer	9.59e-05	0.000392	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CDKN1A—esophageal cancer	9.36e-05	0.000383	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SMAD4—esophageal cancer	9.34e-05	0.000382	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOTCH1—esophageal cancer	9.23e-05	0.000378	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOTCH1—esophageal cancer	9.04e-05	0.00037	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EP300—esophageal cancer	8.91e-05	0.000365	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CREBBP—esophageal cancer	8.78e-05	0.000359	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CREBBP—esophageal cancer	8.37e-05	0.000342	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—EGFR—esophageal cancer	8.22e-05	0.000336	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	8.19e-05	0.000335	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	8.05e-05	0.000329	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—NOS3—esophageal cancer	7.86e-05	0.000322	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	7.86e-05	0.000322	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MYC—esophageal cancer	7.76e-05	0.000318	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	7.69e-05	0.000315	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	7.64e-05	0.000313	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EGFR—esophageal cancer	7.59e-05	0.000311	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOS3—esophageal cancer	7.49e-05	0.000307	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOS3—esophageal cancer	7.33e-05	0.0003	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KDR—esophageal cancer	7.31e-05	0.000299	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTGS2—esophageal cancer	7.19e-05	0.000294	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	7.14e-05	0.000292	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	7.01e-05	0.000287	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	6.99e-05	0.000286	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	6.88e-05	0.000282	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	6.86e-05	0.000281	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CA—esophageal cancer	6.59e-05	0.00027	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TP53—esophageal cancer	6.38e-05	0.000261	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	6.24e-05	0.000255	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCND1—esophageal cancer	6.19e-05	0.000253	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	6.13e-05	0.000251	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCND1—esophageal cancer	6.06e-05	0.000248	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	5.99e-05	0.000245	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—EP300—esophageal cancer	5.98e-05	0.000245	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	5.86e-05	0.00024	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	5.86e-05	0.00024	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EP300—esophageal cancer	5.7e-05	0.000233	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOS3—esophageal cancer	5.59e-05	0.000229	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EP300—esophageal cancer	5.58e-05	0.000228	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	5.32e-05	0.000218	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	5.23e-05	0.000214	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MYC—esophageal cancer	4.97e-05	0.000203	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MYC—esophageal cancer	4.86e-05	0.000199	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EGFR—esophageal cancer	4.86e-05	0.000199	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EGFR—esophageal cancer	4.76e-05	0.000195	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCND1—esophageal cancer	4.62e-05	0.000189	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	4.47e-05	0.000183	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CA—esophageal cancer	4.42e-05	0.000181	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EP300—esophageal cancer	4.25e-05	0.000174	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	4.22e-05	0.000172	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	4.13e-05	0.000169	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TP53—esophageal cancer	4.08e-05	0.000167	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TP53—esophageal cancer	3.99e-05	0.000163	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MYC—esophageal cancer	3.7e-05	0.000152	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EGFR—esophageal cancer	3.62e-05	0.000148	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	3.14e-05	0.000129	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TP53—esophageal cancer	3.04e-05	0.000124	CbGpPWpGaD
